Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gain Therapeutics, Inc.

2.40
-0.0700-2.83%
Volume:177.87K
Turnover:417.96K
Market Cap:63.66M
PE:-2.21
High:2.44
Open:2.44
Low:2.25
Close:2.47
Loading ...

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

THOMSON REUTERS
·
07 Jan

Press Release: Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Dow Jones
·
07 Jan

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

TIPRANKS
·
24 Dec 2024

Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study

MT Newswires Live
·
23 Dec 2024

Gain Therapeutics initiates Phase 1b trial of GT-02287

TIPRANKS
·
23 Dec 2024

Gain Therapeutics Inc - Enrollment Expected to Complete in Spring 2025, Data Expected Mid-2025

THOMSON REUTERS
·
23 Dec 2024

Gain Therapeutics Initiates Phase 1B Clinical Trial of Lead Candidate GT-02287 in People With Gba1 and Idiopathic Parkinson’s Disease

THOMSON REUTERS
·
23 Dec 2024

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

GlobeNewswire
·
23 Dec 2024

Gain Therapeutics To Present At Biotech Showcase 2025

GlobeNewswire
·
11 Dec 2024

Gain Therapeutics Initiated at Buy by Roth MKM

Dow Jones
·
06 Dec 2024

Gain Therapeutics initiated with a Buy at Roth MKM

TIPRANKS
·
06 Dec 2024

Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics

TIPRANKS
·
25 Nov 2024

Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Trials

TIPRANKS
·
21 Nov 2024

Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson’s Disease

TIPRANKS
·
19 Nov 2024

Gain Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate

Benzinga
·
15 Nov 2024